Interleukin 1 Receptor Antagonist and Tumor Necrosis Factor-α Gene Polymorphism in Patients with End-Stage Renal Failure
Authors:
- Kuo-Hsiung ShuKSKuo-Hsiung Shu
- Chi-Hung ChengCCChi-Hung Cheng
- Ming-Ju WuMWMing-Ju Wu
- Cheng-Hsu ChenCCCheng-Hsu Chen
- Wen-Chin LeeWLWen-Chin Lee
- M.D.M.M.D.
Open Access
- 1 January 2005
- journal article
- Published by Taylor & Francis in Renal Failure
- Vol. 27 (1) , 53-57
Abstract
End-stage-renal disease (ESRD) is a final result of various etiologies. Prognostic indicators leading to ESRD in chronic kidney diseases have been studied extensively, of which, genetic factors remain a subject of great concern. Interleukin-1 (IL-1) and tumor necrosis factor-α (TNF-α) are potent proinflammatory cytokines that are involved in several chronic kidney diseases. Studies on cytokine gene polymorphism have revealed important information about the role of genetic factors in disease susceptibility and severity. Gene polymorphism of interleukin-1 receptor antagonist (IL-1ra) and TNF-α were determined in 297 ESRD patients and in 145 normal healthy controls. IL-1ra gene polymorphism was characterized as a variable number of tandem repeats of a 86 bp sequence within intron 2. Five alleles were identified and were designated as IL1RN*1, IL1RN*2, IL1RN*3, IL1RN*4, and IL1RN*5, corresponding to 4,2,5,3, and 6 repeats, respectively. A polymorphism in the promoter region of the TNF-α gene was also studied. This polymorphism involved a guanidine to adenosine transition at position − 308 and was designated as TNF1 (− 308 G) and TNF2 (− 308 A). The genotypes and allele frequencies were compared between patients and control group. The distributions of genotypes of IL-1ra and TNF-α did not differ significantly between ESRD patients and normal controls. Analysis of allele frequencies revealed a trend toward an increase in IL1RN*2 frequency (7.5% versus 3.8 %, p = 0.064) and noncarriage of TNF2 in the patient group (7.2% versus 11.0%, p = 0.076) when compared with the control group. When both alleles were considered together, the patient group had a significantly higher frequency of carriage of IL1RN*2 in combination with noncarriage of TNF2 (p = 0.0468). We conclude that carriage of IL-1RN*2 and noncarriage of TNF2 allele appear to be poor prognostic factors in patients suffering from various chronic renal diseases that eventually enter end-stage renal failure.Keywords
This publication has 20 references indexed in Scilit:
- Quiz page answers December 2003American Journal of Kidney Diseases, 2003
- Impact of interleukin-1 receptor antagonist and tumor necrosis factor-α gene polymorphism on IgA nephropathyKidney International, 2000
- Different gene loci within the HLA‐DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patientsTissue Antigens, 2000
- Presence of the IL‐1RA Allele 2 (IL1RN*2) is Associated with Enhanced IL‐1β Production In VitroScandinavian Journal of Immunology, 1998
- A promoter polymorphism of tumor necrosis factor α associated with systemic lupus erythematosus in African‐AmericansArthritis & Rheumatism, 1997
- Genetic linkage analysis of growth factor loci and end-stage renal disease in African AmericansKidney International, 1997
- Renal disease susceptibility and hypertension are under independent genetic control in the fawn-hooded ratNature Genetics, 1996
- Interleukin-1 in crescentic glomerulonephritisKidney International, 1995
- Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphismClinical and Experimental Immunology, 1995
- Single base polymorphism in the human Tumour Necrosis Factor alpha (TNFα) gene detectable by Ncol restriction of PCR productHuman Molecular Genetics, 1992